Rua Bioscience has approved a $600,000 convertible note facility aimed at boosting inventory purchases to accelerate its UK market expansion following a major distribution deal.
- Convertible note facility capped at NZ$600,000
- Unsecured notes convert to shares at minimum $0.025 each
- Facility targets inventory funding for UK market growth
- Conversion triggered by capital raise over NZ$1.5 million or 12-month maturity
- Supports Rua's recent NZ$10m UK medicinal cannabis contract
Convertible Note Facility to Accelerate UK Expansion
Rua Bioscience (NZX:RUA) has secured board approval for a convertible note facility worth up to NZ$600,000, designed to fast-track inventory purchases and underpin sales growth as the company pushes deeper into the UK market. The unsecured notes bear interest for up to 12 months and convert into fully paid ordinary shares either after a year at Rua’s discretion or automatically if a capital raise exceeding NZ$1.5 million occurs within that timeframe.
Conversion Terms and Potential Dilution
The conversion price is set at the lower of NZ$0.025 per share or the price offered in any qualifying capital raise. Should the facility be fully drawn and converted at the floor price, Rua would issue approximately 24 million new shares, excluding accrued interest. This introduces a meaningful potential dilution, reflecting the trade-off between immediate working capital needs and shareholder value.
Strategic Alignment with Recent UK Contract
This financing move aligns directly with Rua’s recent NZ$10 million UK medical cannabis distribution deal, which commits the company to supply New Zealand-grown products to a major UK distributor over two years. The facility aims to ensure sufficient inventory availability to capitalise on this contract and accelerate market penetration in a UK sector that has seen rapid growth.
Working Capital Needs Amid Global Expansion
Rua’s Chief Executive Paul Naske highlighted the increased working capital demands accompanying the company’s global expansion. The convertible note facility offers a flexible funding mechanism without immediate equity dilution, balancing the need for growth capital with prudent financial management.
Uncertainties Around Interest and Timing
While the convertible note terms specify interest-bearing status for up to 12 months, the exact interest rate remains undisclosed, leaving some uncertainty over the cost of this capital. Additionally, the timing of any conversion depends on future capital raising activities or the 12-month maturity, factors investors will watch closely for their impact on Rua’s capital structure.
Bottom Line?
Rua’s convertible note facility is a tactical lever to fund inventory for UK growth, but investors should monitor potential dilution and conversion triggers closely.
Questions in the middle?
- What interest rate will Rua Bioscience ultimately apply to the convertible notes?
- Will Rua secure a capital raise exceeding NZ$1.5 million within 12 months triggering automatic conversion?
- How quickly will inventory funded by this facility translate into UK sales growth?